Femasys (FEMY) Gross Margin (2020 - 2026)
Femasys' (FEMY) quarterly Gross Margin came in at 57.08% in Q2 2026, down 428.0% on a YoY basis from 17.4% in Q2 2025, and down 6.97% quarter-over-quarter from 61.35% in Q2 2025.
Powered by 
Analysis
Femasys (FEMY) Gross Margin (2020 - 2026) Analysis & Trends
Femasys (FEMY) has reported Gross Margin for 7 consecutive years, with 57.08% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gross Margin fell 428.0% year-over-year to 57.08%; the trailing twelve-month figure through Jun 2026 stood at 63.32% (down 177.0% YoY), and the FY2025 full-year result was 61.96%, down 459.0% from the prior year.
- Gross Margin retreated to 57.08% in Q2 2026 per FEMY's latest filing, from 61.35% in the prior quarter.
- Across five years, Gross Margin topped out at 67.35% in Q1 2024 and bottomed at 57.08% in Q2 2026.
- Historically, Gross Margin has averaged 64.16% across 5 years, with a median of 64.73% in 2023.
- The sharpest annual moves came in 2022 and 2024: Gross Margin plunged 1120 bps in 2022, then surged 365 bps in 2024.
- Over 5 years, Gross Margin stood at 63.52% in 2022, then decreased by 0 bps to 63.26% in 2023, then climbed by 6 bps to 66.92% in 2024, then fell by 8 bps to 61.35% in 2025, then dropped by 7 bps to 57.08% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 57.08%, 61.35%, and 65.64% for Q2 2026, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 57.71% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 67.78% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 64.99% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 68.27% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 70.71% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 77.46% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 60.21% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 63.44% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 45.84% |
| 10 | Femasys | 9.37 Mn | 7.92 Mn | 189,391.00 | 57.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 57.08% |
| Jun 30, 2025 | 61.35% |
| Mar 31, 2025 | 65.64% |
| Dec 31, 2024 | 66.92% |
| Sep 30, 2024 | 65.61% |
| Jun 30, 2024 | 66.98% |
| Mar 31, 2024 | 67.35% |
| Dec 31, 2023 | 63.26% |
| Sep 30, 2023 | 64.73% |
| Jun 30, 2023 | 65.53% |
| Mar 31, 2023 | 64.24% |
| Dec 31, 2022 | 63.52% |
| Sep 30, 2022 | 62.17% |
| Jun 30, 2022 | 66.23% |
| Mar 31, 2022 | 61.83% |
| Dec 31, 2021 | 74.71% |
| Sep 30, 2021 | 60.90% |
| Jun 30, 2021 | 66.99% |
| Mar 31, 2021 | 71.79% |
| Dec 31, 2020 | 68.81% |